Receptor for Advanced Glycation End Products

"Receptor for Advanced Glycation End Products" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A single-pass transmembrane CELL SURFACE RECEPTOR that binds ADVANCED GLYCATION END PRODUCTS to mediate cellular responses to both acute and chronic vascular inflammation in conditions such as ATHEROSCLEROSIS and DIABETES MELLITUS, TYPE 2. It also binds AMYLOID BETA PEPTIDES and the ALARMINS - S100A12 and S100 CALCIUM BINDING PROTEIN BETA SUBUNIT.

Descriptor ID	D000067759
MeSH Number(s)	D12.776.543.750.615
Concept/Terms	Receptor for Advanced Glycation End Products Receptor for Advanced Glycation End Products AGE Receptor Receptor, AGE RAGE (Receptor for Advanced Glycation End Products) Advanced Glycosylation End Product Receptors Advanced Glycosylation End-Product Receptor Advanced Glycosylation End Product Receptor Advanced Glycosylation End-Product Receptors Advanced Glycosylation Endproduct Receptors Receptor for Advanced Glycation End Products (RAGE) Receptor for Advanced Glycation Endproducts Receptor, Advanced Glycosylation End-Product Receptor, Advanced Glycosylation End Product Receptor, Advanced Glycosylation End-Products Receptor, Advanced Glycosylation End Products Advanced Glycosylation End Product-Specific Receptor Advanced Glycosylation End Product Specific Receptor AGER Protein Protein, AGER Amphoterin Receptor Receptor, Amphoterin

Below are MeSH descriptors whose meaning is more general than "Receptor for Advanced Glycation End Products".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Membrane Proteins [D12.776.543]
Receptors, Cell Surface [D12.776.543.750]
Receptor for Advanced Glycation End Products [D12.776.543.750.615]

Below are MeSH descriptors whose meaning is related to "Receptor for Advanced Glycation End Products".

Below are MeSH descriptors whose meaning is more specific than "Receptor for Advanced Glycation End Products".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Receptor for Advanced Glycation End Products" by people in this website by year, and whether "Receptor for Advanced Glycation End Products" was a major or minor topic of these publications.

Bar chart showing 14 publications over 10 distinct years, with a maximum of 2 publications in 2003 and 2004 and 2012 and 2015

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2000	0	1	1
2003	0	2	2
2004	0	2	2
2010	0	1	1
2011	0	1	1
2012	0	2	2
2015	1	1	2
2017	1	0	1
2020	1	0	1
2022	0	1	1

Below are the most recent publications written about "Receptor for Advanced Glycation End Products" by people in Profiles.

Kinscherf NA, Pehar M. Role and Therapeutic Potential of RAGE Signaling in Neurodegeneration. Curr Drug Targets. 2022; 23(12):1191-1209.

View in: PubMed
Liu L, Killoy KM, Vargas MR, Yamamoto Y, Pehar M. Effects of RAGE inhibition on the progression of the disease in hSOD1G93A ALS mice. Pharmacol Res Perspect. 2020 08; 8(4):e00636.

View in: PubMed
Kim MJ, Vargas MR, Harlan BA, Killoy KM, Ball LE, Comte-Walters S, Gooz M, Yamamoto Y, Beckman JS, Barbeito L, Pehar M. Nitration and Glycation Turn Mature NGF into a Toxic Factor for Motor Neurons: A Role for p75NTR and RAGE Signaling in ALS. Antioxid Redox Signal. 2018 06 20; 28(18):1587-1602.

View in: PubMed
Sambamurthy N, Leme AS, Oury TD, Shapiro SD. The receptor for advanced glycation end products (RAGE) contributes to the progression of emphysema in mice. PLoS One. 2015; 10(3):e0118979.

View in: PubMed
Nasser MW, Wani NA, Ahirwar DK, Powell CA, Ravi J, Elbaz M, Zhao H, Padilla L, Zhang X, Shilo K, Ostrowski M, Shapiro C, Carson WE, Ganju RK. RAGE mediates S100A7-induced breast cancer growth and metastasis by modulating the tumor microenvironment. Cancer Res. 2015 Mar 15; 75(6):974-85.

View in: PubMed
Yu Y, Hanssen KF, Kalyanaraman V, Chirindel A, Jenkins AJ, Nankervis AJ, Torjesen PA, Scholz H, Henriksen T, Lorentzen B, Garg SK, Menard MK, Hammad SM, Scardo JA, Stanley JR, Wu M, Basu A, Aston CE, Lyons TJ. Reduced soluble receptor for advanced glycation end-products (sRAGE) scavenger capacity precedes pre-eclampsia in Type 1 diabetes. BJOG. 2012 Nov; 119(12):1512-20.

View in: PubMed
Webster SJ, Mruthinti S, Hill WD, Buccafusco JJ, Terry AV. An aqueous orally active vaccine targeted against a RAGE/AB complex as a novel therapeutic for Alzheimer's disease. Neuromolecular Med. 2012 Jun; 14(2):119-30.

View in: PubMed
Nasser MW, Qamri Z, Deol YS, Ravi J, Powell CA, Trikha P, Schwendener RA, Bai XF, Shilo K, Zou X, Leone G, Wolf R, Yuspa SH, Ganju RK. S100A7 enhances mammary tumorigenesis through upregulation of inflammatory pathways. Cancer Res. 2012 Feb 01; 72(3):604-15.

View in: PubMed
Ramsgaard L, Englert JM, Tobolewski J, Tomai L, Fattman CL, Leme AS, Kaynar AM, Shapiro SD, Enghild JJ, Oury TD. The role of the receptor for advanced glycation end-products in a murine model of silicosis. PLoS One. 2010 Mar 19; 5(3):e9604.

View in: PubMed
Arancio O, Zhang HP, Chen X, Lin C, Trinchese F, Puzzo D, Liu S, Hegde A, Yan SF, Stern A, Luddy JS, Lue LF, Walker DG, Roher A, Buttini M, Mucke L, Li W, Schmidt AM, Kindy M, Hyslop PA, Stern DM, Du Yan SS. RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J. 2004 Oct 13; 23(20):4096-105.

View in: PubMed

People

Explore

Similar Concepts

Top Journals